$73.26
1.13[1.57%]
At close: Apr 26
$73.26
0[0.00%]
After Hours: 4:20PM EDT
Intra-Cellular Therapies
(NASDAQ:ITCI)Intra-Cellular Therapies Stock (NASDAQ:ITCI), Analyst Ratings, Price Targets, Predictions
Intra-Cellular Therapies Inc has a consensus price target of $84.88, established from looking at the 71 latest analyst ratings. The last 3 analyst ratings were released from Cantor Fitzgerald, Canaccord Genuity, and Needham on April 24, 2024, April 23, 2024, and April 22, 2024. With an average price target of $105.67 between Cantor Fitzgerald, Canaccord Genuity, and Needham, there's an implied 44.24% upside for Intra-Cellular Therapies Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Cantor Fitzgerald
Canaccord Genuity
Needham
Mizuho
Goldman Sachs
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Intra-Cellular Therapies
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 04/24/2024 | ITCI | Buy Now | Intra-Cellular Therapies | $73.26 | 63.8% | Cantor Fitzgerald | Charles Duncan | → $120 | Reiterates | Overweight → Overweight | Get Alert |
| 04/23/2024 | ITCI | Buy Now | Intra-Cellular Therapies | $73.26 | 46.06% | Canaccord Genuity | Sumant Kulkarni | $100 → $107 | Maintains | Buy | Get Alert |
| 04/22/2024 | ITCI | Buy Now | Intra-Cellular Therapies | $73.26 | 22.85% | Needham | Ami Fadia | $82 → $90 | Maintains | Buy | Get Alert |
| 04/22/2024 | ITCI | Buy Now | Intra-Cellular Therapies | $73.26 | 31.04% | Mizuho | Graig Suvannavejh | $82 → $96 | Maintains | Buy | Get Alert |
| 04/17/2024 | ITCI | Buy Now | Intra-Cellular Therapies | $73.26 | 5.11% | Goldman Sachs | Corinne Jenkins | $67 → $77 | Maintains | Neutral | Get Alert |
| 04/17/2024 | ITCI | Buy Now | Intra-Cellular Therapies | $73.26 | 24.22% | B of A Securities | Jason Gerberry | $82 → $91 | Maintains | Buy | Get Alert |
| 04/17/2024 | ITCI | Buy Now | Intra-Cellular Therapies | $73.26 | 40.6% | Baird | Joel Beatty | $83 → $103 | Maintains | Outperform | Get Alert |
| 04/17/2024 | ITCI | Buy Now | Intra-Cellular Therapies | $73.26 | 22.85% | TD Cowen | Joseph Thome | $80 → $90 | Maintains | Buy | Get Alert |
| 04/16/2024 | ITCI | Buy Now | Intra-Cellular Therapies | $73.26 | 11.93% | Needham | Ami Fadia | → $82 | Reiterates | Buy → Buy | Get Alert |
| 04/05/2024 | ITCI | Buy Now | Intra-Cellular Therapies | $73.26 | 11.93% | Needham | Ami Fadia | → $82 | Reiterates | Buy → Buy | Get Alert |
| 04/03/2024 | ITCI | Buy Now | Intra-Cellular Therapies | $73.26 | 17.39% | RBC Capital | Brian Abrahams | → $86 | Reiterates | Outperform → Outperform | Get Alert |
| 02/23/2024 | ITCI | Buy Now | Intra-Cellular Therapies | $73.26 | 37.87% | Cantor Fitzgerald | Charles Duncan | → $101 | Reiterates | Overweight → Overweight | Get Alert |
| 02/23/2024 | ITCI | Buy Now | Intra-Cellular Therapies | $73.26 | 17.39% | RBC Capital | Brian Abrahams | → $86 | Reiterates | Outperform → Outperform | Get Alert |
| 02/23/2024 | ITCI | Buy Now | Intra-Cellular Therapies | $73.26 | 36.5% | Canaccord Genuity | Sumant Kulkarni | $101 → $100 | Maintains | Buy | Get Alert |
| 02/23/2024 | ITCI | Buy Now | Intra-Cellular Therapies | $73.26 | 11.93% | Needham | Ami Fadia | $72 → $82 | Maintains | Buy | Get Alert |
| 02/16/2024 | ITCI | Buy Now | Intra-Cellular Therapies | $73.26 | 11.93% | Mizuho | Graig Suvannavejh | $76 → $82 | Maintains | Buy | Get Alert |
| 01/31/2024 | ITCI | Buy Now | Intra-Cellular Therapies | $73.26 | 17.39% | RBC Capital | Brian Abrahams | → $86 | Reiterates | Outperform → Outperform | Get Alert |
| 01/18/2024 | ITCI | Buy Now | Intra-Cellular Therapies | $73.26 | -12.64% | Goldman Sachs | Corinne Jenkins | $58 → $64 | Maintains | Neutral | Get Alert |
| 01/03/2024 | ITCI | Buy Now | Intra-Cellular Therapies | $73.26 | 13.3% | Baird | Joel Beatty | → $83 | Initiates | → Outperform | Get Alert |
FAQ
What is the target price for Intra-Cellular Therapies (ITCI)?
The latest price target for Intra-Cellular Therapies (NASDAQ: ITCI) was reported by Cantor Fitzgerald on April 24, 2024. The analyst firm set a price target for $120.00 expecting ITCI to rise to within 12 months (a possible 63.80% upside). 38 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Intra-Cellular Therapies (ITCI)?
The latest analyst rating for Intra-Cellular Therapies (NASDAQ: ITCI) was provided by Cantor Fitzgerald, and Intra-Cellular Therapies reiterated their overweight rating.
When was the last upgrade for Intra-Cellular Therapies (ITCI)?
There is no last upgrade for Intra-Cellular Therapies.
When was the last downgrade for Intra-Cellular Therapies (ITCI)?
The last downgrade for Intra-Cellular Therapies Inc happened on August 22, 2022 when Goldman Sachs changed their price target from $64 to $49 for Intra-Cellular Therapies Inc.
When is the next analyst rating going to be posted or updated for Intra-Cellular Therapies (ITCI)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Intra-Cellular Therapies, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Intra-Cellular Therapies was filed on April 24, 2024 so you should expect the next rating to be made available sometime around April 24, 2025.
Is the Analyst Rating Intra-Cellular Therapies (ITCI) correct?
While ratings are subjective and will change, the latest Intra-Cellular Therapies (ITCI) rating was a reiterated with a price target of $0.00 to $120.00. The current price Intra-Cellular Therapies (ITCI) is trading at is $73.26, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.